Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Devangi Desai

Internal Medicine Sparks, NV Medical Doctor

NPI 1710155163 CMS profile 349669

202 Los Altos Pkwy, Sparks, NV 89436

Open in the dashboard

General payments

$4,220

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Devangi Desai of Sparks, NV is reported in the CMS Open Payments database as having received $4,220 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $243 8
2024 General $402 9
2023 General $241 7
2022 General $158 8
2021 General $562 20
2020 General $2,262 15
2019 General $352 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Devangi Desai
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Devangi Desai were reported at $243. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Devangi Desai Internal Medicine median Middle half National median
2019 $352 $159 $48–$570 $163
2020 $2,262 $119 $33–$402 $114
2021 $562 $135 $37–$521 $132
2022 $158 $141 $42–$496 $149
2023 $241 $149 $45–$519 $160
2024 $402 $154 $47–$537 $164
2025 $243 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $2,213 6 payments
  2. Abbott Laboratories $665 19 payments
  3. Edwards Lifesciences Corporation $377 11 payments
  4. AbbVie, Inc. $202 10 payments
  5. GlaxoSmithKline, LLC. $135 9 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $100 2 payments
  7. Boston Scientific Corporation $94 2 payments
  8. E.R. Squibb & Sons, L.L.C. $62 3 payments
  9. Pfizer Inc. $53 3 payments
  10. Medtronic Vascular, Inc. $50 1 payment
  11. Other $271 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,220 81 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $2,213 6 payments
  2. CARDIOMEMS $203 2 payments
  3. MitraClip System $203 4 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $144 3 payments
  5. VRAYLAR $129 6 payments
  6. Mitra Clip system $121 7 payments
  7. PASCAL $110 2 payments
  8. SAPIEN 3 Ultra RESILIA $108 5 payments
  9. BEXSERO $104 7 payments
  10. JARDIANCE $100 2 payments
  11. Other $964 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

5,604

Median for Internal Medicine: 777

Drug cost

$584,042

Median for Internal Medicine: $73,373

Branded share of claims

18.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 96 $145,876
Jardiance Empagliflozin Brand 91 $110,935
Trulicity Dulaglutide Brand 41 $59,488
Eliquis Apixaban Brand 33 $48,044
Tresiba Flextouch U-200 Insulin Degludec Brand 20 $29,696
Mounjaro Tirzepatide Brand 15 $23,820
Synjardy Empagliflozin/Metformin Hcl Brand 15 $20,978
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $16,140
Januvia Sitagliptin Phosphate Brand 12 $15,416
Breo Ellipta Fluticasone/Vilanterol Brand 18 $11,805

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$103,475

Medicare's payments for the services billed

Medicare patients

412

Average age 75

Services billed

1,305

269 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 42%
Ischemic heart disease 25%
Chronic kidney disease 22%
Diabetes 21%
Depression 18%
Osteoporosis 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record